Orasis enrolls patients in phase 2b for presbyopia eye drop
Orasis Pharmaceuticals is developing a corrective eye drop for the treatment of presbyopia as an alternative to reading glasses and announced that it is beginning its phase 2b clinical study in the U.S. evaluating CSF-1.
CSF-1 has the potential to restore near vision and offer an alternative to current treatment options, which are either cumbersome or invasive, Elad Kedar, Orasis CEO said in the company announcement.
The phase 2b is a multicenter, double-masked trial in the U.S. enrolling 150 participants to evaluate the efficacy and safety of CSF-1 and started patient enrollment in February. All study sites are actively recruiting participants ages 45 to 64 years with presbyopia, according to the company.